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Summary.-A 51Cr-release test was developed for the detection of cell-mediated
cytotoxicity against transplanted solid chemically induced rat tumours, and the
findings were compared with those obtained in parallel tests using a microcyto-
toxicity assay. It was necessary to incorporate several modifications of the original
Brunner assay (Brunner et al., 1968) in order to increase the sensitivity of the test as
applied to long-term tumour lines maintained as glass-adherent cultures. These
included: 1. preincubation of labelled tumour cells at 37°C for 3-4 h before addition of
effector cells; 2. preincubation of effector cells at 37°C for 12 h before addition to
target cells; 3. upon admixture of target and effector cells, intimate cell contact was
established by gentle centrifugation; 4. after incubation of target and effector cells at
37°C, a further incubation for 1 h at 45°C was included to complete the release of
51Cr from non-viable cells. Maximal cytotoxicity of tumour-bearer effector cells
was detected after 12 h incubation of lymphoid and target cells at a ratio of 200:1.
Spleen cells from tumour-bearing rats during the first 2 weeks of tumour growth
exhibited the same pattern of reactivity in the 5'Cr-release test and the microcyto-
toxicity assay, although significant reduction in target-cell numbers was more
frequently recorded using the microcytotoxicity assay. Tumour-bearer spleen cells
showed reactivity against the homologous tumour as well as against unrelated
tumours. Using either assay, pre-exposure of effector cells to 3M KCI extracts of
tumour was found to inhibit their effect on tumour cells most frequently in tests in
which the effector-cell donor, soluble extract and target cell were of the same tumour
line.
THE 51Cr-release test and the micro-
cytotoxicity assay represent 2 important
test systems in common use for the
demonstration of lymphoid cell-mediated
cytotoxic reactions against tumour cells.
A major use of the 51Cr-release test in the
study of tumour immunity has been with
suspension cultures of tumour cells of
lymphoid origin. The test is considered to
generate data which reflect direct cell
lvsis (Cerottini and Brunner, 1974). Con-
versely, with the microcytotoxicity assay
(Takasugi and Klein, 1970; Hellstrom et
al., 1971) cell lysis and cytostasis, as well
as impairment of cell functions leading to
detachment from plastic surfaces, may be
measured by visual counting of remaining
adherent tumour cells. Disparities be-
tween the assays may be the product of
the particular assay employed (e.g. Plata
et al., 1974) or may be due to the different
nature of effector cells and cytotoxic
pathways operating in these tests. Evi-
dence has been obtained that in the short-
term 51Cr-release test, cytolysis is mediated
by T cells (Leclerc et al., 1973; Cerottini
and Brunner, 1974). The situation with
the microcytotoxicity assay is less well
defined and both T (Fossati, Holden and
Herberman, 1975) and non-T (Plata et al.,
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1974; Lamon et al., 1973; Lavrin et al.,
1973) cell killing have been implicated.
Furthermore, the studies of Ortiz de
Landazuri and Herberman (1972) suggest
that the cytotoxicity of lymphoid cells
may involve in vitro activation of cellular
immune response during incubation. Pos-
sibly, depending on the test conditions,
both assays may detect T, B and non-
lymphoid cell killing, which could explain
that no consistent differences were detec-
ted between the 2 assays when cytotoxic
responses of T- or B-enriched subfractions
were tested in both assays (e.g. Hersey
et al., 1975). A further possibility is that
during the 48-h incubation of target and
effector cells in the microcytotoxicity
assay, 2 T-cell populations may be active:
cytotoxic T cells as well as initially non-
lytic secondary T cells which acquire
cytotoxic reactivity during the first 24 h
of the test period (Trostmann et al., 1976).
The present study describes an attempt
to modify the Brunner 5'Cr-release test
(Brunner et al., 1968) in order to allow
evaluation of tumour-bearer lymphoid-
cell-mediated cytotoxicity to cells from
transplanted solid chemically induced rat
tumours, cultured as long-term, glass-
adherent cell lines. For comparative
purposes, parallel tests were performed
using the microcytotoxicity assay. The
sensitivities of the 2 test systems were also
compared in their ability to detect inhibi-
tion of cytotoxicity after brief exposure
of effector cell preparations to extracts
containing soluble tumour antigen.
MATERIAL AND METHODS
Target tumour cells and lymphoid cells.-
Cell cultures from the transplanted rat
hepatomas D191 and D192 and sarcomas
Mc7 and Mc57 were used. Details of the
establishment and maintenance of these cell
lines have been previously described, and the
preparation of tumour-bearer lymph-node
cells (LNC) and spleen cells, as well as
lymphoid cells from normal donors, was also
carried out according to Zoller, Price and
Baldwin (1975). Lymphoid cells used in the
51Cr-release test were separated by gradient
centrifugation on Ficoll-Triosil (Boyum,
1968) and were incubated for a further 12 h
at 37°C in Eagle's-HEPES buffer + 10% calf
serum, washed x 5 by centrifugation with
Hanks' balanced salt solution and suspended
in Eagle's-HEPES + 10% calf serum. Cell
viability after these procedures was greater
than 90% as judged by trypan blue exclusion.
For macrophage depletion, the effector-
cell population, in addition to the procedure
described, was incubated with carbonyl iron
for 30 min at 37°C. After removal of
ingested carbonyl iron by a magnet, a further
Ficoll-Triosil gradient centrifugation was
performed.
51Cr-labelling of target tumour cells.-
Target tumour cells (5 X 106 to 107) were
labelled by incubation with 100 FLCi of
[51Cr]Na2CrO4 (Radiochemical Centre, Amer-
sham) in a total volume of 1 to 2 ml of
Eagle's-HEPES + 10% calf serum for 1 h at
37°C. The cells were washed with Hanks'
balanced salt solution and suspended in
Eagle's-HEPES + 10% calf serum. After
further incubation at 37°C for 3-4 h, the cells
were washed twice with Hanks' balanced salt
solution and finally suspended in Eagle's-
HEPES buffer + 10% calf serum.
51Cr-release test.-Labelled tumour target
cells (0.1 ml at 105 cells/ml) were mixed with
lymphoid cells (0.1 ml at 107 or 2 x 107 cells/
ml). Triplicate tests were performed in
(9.5 x 63.5)mm stoppered polystyrene
round-bottom tubes. Cells were sedimented
at 300 g for 3 min before incubation. In
preliminary tests, tubes were incubated at
37°C for 2, 4, 8, 12 and 18 h. Finally a
standard incubation time of 12 h was
adopted. The release of 51Cr from damaged
target cells was completed by incubation at
45°C for 1 h. For the estimation of released
51Cr, phosphate-buffered saline (1-8 ml) was
added to each tube and, after centrifugation
at 800 g for 5 min, 1 ml of supernatant and
1 ml of remaining supernatant plus cell
sediment were counted in a LKB-Wallac
Automatic Gamma Counter. Percentage
51Cr release was calculated as follows:
% 51Cr release
( 2 x supernatant
upernatant + (supernatant X 100.
+ cellsediment)
Percentage cytotoxicity was calculated using
the formula:
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% cytotoxicity - c 6 Xa
where a = % 51Cr release from target cells in
the presence of normal or tumour-bearer
lymphoid cells, b = % 51Cr release from
target cells exposed to medium alone and
c = % 51Cr release from target cells lysed by
incubation at 37°C in water (041 ml cell
suspension + 1-9 ml water). The 51Cr re-
lease from tumour cells in the presence of
normal lymphoid cells compared withmedium
control samples was determined in each
experiment. For each of the 4 tumour lines
used, the mean % 51Cr release and standard
deviation was calculated as shown in Table I.
Tests with tumour-bearer lymphoid cells
which gave a % 51Cr release greater than the
mean % 51Cr release plus two standard
deviations for cells from that tumour line in
the presence of normal lymphoid cells, were
taken to represent a significant cytotoxic
reaction (Table I).
TABLE J.-51Cr Release from Tumour Cells
in the Presence of Lymphoid Cells from
Normal Rats
Tumour cell Mean ± s.d. Mean + (2 x s.d.)*
0/
0o
Sarcoma Mc7
Sarcoma Mc57
Hepatoma D191
Hepatoma D192
0-5±2-1
0* 7±2 * 9
1 *0±2-0
0-5±2 *4
4-7
6 -5
5 0
5-3
* These values are the lower limit for significant
release of 5'Cr with tumour-bearer lymphoid cells.
Microcytotoxicity assay.-The microcyto-
toxicity assay was performed using an
effector cell to target cell ratio of 1000 : 1 as
previously described (Zoller et al., 1975).
Cytotoxicity inhibition test.-3M KCI ex-
tracts of tumours were prepared according to
Z6ller, Price and Baldwin (1976). Lymphoid
cells from normal and tumour-bearing rats
were incubated at 370C for 60 min with
tumour extracts at 1 mg protein/16 cells and
in control samples with Eagle's-HEPES
buffer alone. The cells were sedimented by
centrifugation, the supernatant was dis-
carded, and the cells were resuspended in
Eagle's-HEPES buffer prior to their use in
the 51Cr-release test or microcytotoxicity
assay. The percentage inhibition of cyto-
toxicity was calculated as follows:
Percentage inhibition =
% cytotoxicity % cytotoxicityof
of untreated - extract-treated
lymphoid cells lymphoid cells x 100.
% cytotoxicity of untreated
lymphoid cells
In " specific " test combinations, target cells,
extract and the tumour of the effector-cell
donor were derived from the same tumour
line. In " cross " test combinations, the
extract and the tumour of the effector-cell
donor were derived from the same tumour
line, but target cells were derived from a
different tumour line.
RESULTS
Test procedure
Using the labelling conditions de-
scribed, an uptake of [51Cr]Na2CrO4
giving approximately 1000 ct/min/103 cells
was obtained with each of the 4 tumour
lines examined. In preliminary tests,
when target cells were used directly after
labelling, a spontaneous release of 51Cr of
up to 40-50% was observed in medium
control samples after an incubation period
of 12 h at 37TC. However, this was
reduced to 20-35% when labelled target
cells were incubated at 3700 for 3-4 h and
then washed prior to a 12-h incubation at
37 (C with the effector cells. In water-
lysis samples, between 80 and 90% of the
total 5'Cr uptake was released during 12 h.
In order to reveal cell-mediated re-
activity, it was necessary to incubate
lymphoid cells for 12 h at 3700 before
addition to tumour target cells. The
optimal ratios ofeffector: target cell were
determined to be 200 : 1 and 100: 1, since
with lower numbers of lymphoid cells no
cytotoxicity was detected in tumour-
bearer effector-cell preparations, whereas
when higher numbers of lymphoid cells
were tested (at effector : target cell ratios
of 500 : 1, 1000 : 1 and 2000: 1) the
release of radiolabel declined: i.e. the
percentage release of 51Cr from target cells
in the presence of normal and tumour-
bearer lymphoid cells was reduced. In
such a situation it was not possible to
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determine meaningful values for tumour-
bearer effector-cell cytotoxicity by com-
parison with medium control samples. As
shown in Table I, at the ratios of 200: 1
and 100: 1, the mean 5TCr release in
samples with normal lymphoid cells did
not differ from medium control samples by
more than approximately 1%.
Fig. 1 illustrates the results of a
representative time-course study using
Time (h)
FIG. 1.--Development of hepatoma-D192-
bearer lymphoid-cell cytotoxicity for
hepatoma D192 cells with increasing
incubation times oftarget cells with effector
cells. Labelled target cells were pre-
incubated for 4 h and effector cells were
preincubated for 12 h at 37°C. The ratio
of effector to target cells was 200: 1.
(A A, Tumour-bearer spleen cells; 0 ,
Tumour-bearer lymph-node cells.)
hepatoma D192-bearer lymph-node and
spleen cells. In this experiment, as well
as in comparable time-course studies with
other target-cell lines, there was little
indication ofsignificant cytotoxic reaction
before at least 8 h and the effect was most
pronounced after incubation for 12 h.
After incubation for 18 h or longer, a high
release of 51Cr was obtained in samples
exposed to either tumour-bearer or normal
lymphoid cells, making a calculation of
cytotoxicity by comparison with the
medium control samples unacceptable.
When calculating the specific 5'Cr release
(Fig. 1) by comparison to samples with
normal lymphoid cells, the loss in sensi-
tivity was shown by a reduction of the
specific 5'Cr release.
No difference in the cytotoxic activities
of tumour-bearer lymph-node, spleen and
peritoneal cells were detected. Further-
more, the depletion of macrophages by
carbonyl iron treatment did not alter the
cytotoxicity significantly. This is demon-
strated for D191 target and effector cells
in Table II.
In all subsequent tests described, an
incubation period of 12 h was employed,
and spleen cells were used exclusively as
effector cells at a ratio of 200 1 to the
target tumour cells.
Characterization of tumour-bearer effector-
cell cytotoxicity
Using the criterion of significance
defined in Material and Methods, the
TABLE JJ.-Cytotoxicity ofTumour-bearerLymph Node (LNC), Spleen (Sp),andPeritoneal
Cells (PC). Effect of Macrophage Depletion (MD) (Target Cell: D192)
% 51Cr release (% cytotoxicity)
Effector cell population*
LNC
LNC: MD
Sp
Sp: MD
PC
Medium control
Lysis sample
6 dayt
38-1 (18-3)
39-4 (20 5)
37-8 (17-9)
44 - 5 (28 9)
42-5 (25-6)
26*9
87-8
7 dayt
43-4 (27-1)
43-0 (26 4)
39-0 (19-9)
40-1 (21-7)
44 -2 (28-4)
* Ratio of effector: target cell; 200: 1.
t Effector cells harvested on the 6th, 8th and 9th days after tumour implantation.
9 dayt
37-0 (16-6)
37-2 (16-9)
38-2 (18-6)
39 -4 (20 5)
39-1 (20 0)
-~~~~~~~~~~~~~
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frequency of tumour-bearer cell-mediated
cytotoxic reactions was analysedin specific
and cross test combinations, the results
being summarized in Table III. Tumour-
bearer spleen cells were taken 4-14 days
after tumour implantation. From Table
III it is evident that each tumour line
TABLE III.-Frequency of Tumour-bearer
Spleen-cell Cytotoxic Reactions inSpecific
and Cross Tests
Target
tumour
Sarcoma
Mc7
Sarcoma
Mc57
Hepatoma
D191
Hepatoma
D192
Test
combi-
nation*
Specific
Cross
Specific
Cross
Specific
Cross
Specific
Cross
No. cytotoxic reactions (%O)
No. tests
27/34 (79)
18/27 (67)
5/21 (24)
9/17 (53)
17/31 (55)
14/19 (74)
7/11 (64)
8/16 (50)
* Specific: spleen cells from donors bearing same
tumour as that used as target cells. Cross: spleen
cells from donors bearing a tumour different from
that used as target cells.
showed broadly similar susceptibility as
release of 51Cr in the presence of tumour-
bearer spleen cells in either specific or
cross test combinations. The highest
incidence of cytotoxicity was observed
using effector cells from rats bearing their
tumour for 5-7 days. This is shown in
specific and cross test combinations for
spleen cells from D191-tumour-bearing
rats (Table IV). After more than 2 weeks
of tumour growth, tumour-bearer lym-
phoid-cell reactivity was diminished. The
TABLE IV.-Cytotoxicity of Spleen Cells
From Rats at Different Times after
Implantation of Hepatoma D191
No. cytotoxic reactions (%)
Days after No. tests
tumour , _ _ _A
implantation Specific* Cross*
2-4 10/13 (77) 3/5 (60)
5-7 16/17 (94) 10/13 (77)
8-10 5/8 (63) 6/16 (38)
11-13 6/11 (55) 2/8 (25)
14-18 8/15 (53) 2/7 (29)
* Specific: spleen cells from rats bearing hepa-
toma D191 were tested against D191 target cells.
Cross: D191 tumour-bearer spleen cells were tested
against different target cells.
The ratio of effector target cells was 200 : 1.
other 3 tumour lines expressed similar
patterns ofreactivity.
For further evaluation of tumour-
bearer effector-cell cytotoxicity, spleen
cells were pretreated with 3M KCI extracts
of tumours, and then assayed for their
cytotoxicity against tumour cells. In
theseexperiments, effector cells were taken
from rats 5-7 days after tumour implant-
ation, andgave abasiccytotoxicity > 10%.
In specific test combinations, the
mean cytotoxicity of spleen cells exposed
to 3M KCI extracts was significantly less
Specific Tests
30T
201-
U
.X O
0
4-
0
on-
-10I
p< 0.001
9
Spleen (34)
CrossTests
s
Spleen
(35)
FIG. 2.-Inhibition of tumour-bearer cell
cytotoxicity for tumour cells by 3M KCI
extracts of tumours. Open columns:
medium-treated effector cells. Shaded
columns: extract-treated effector cells.
In specific tests, homologous combinations
of tumour cells, effector cells and tumour
extract were used. In cross tests, tumour-
bearer effector cells were reacted against
cells of another tumour line, and the
inhibitory action of the extract from the
same tumour asthatbornebythelymphoid-
cell donor was assessed. In parentheses:
number oftests ineach combination. Bars:
the standard deviation of the tests.
L-
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than that of spleen cells exposed to
medium alone (2.3% compared to 18'5%)
(Fig. 2). Table V summarizes our experi-
ments, showing that in 23/34 (71%) of
specific tests, cytotoxicity was inhibited
> than 50%. In cross test combinations,
where the tumour-bearer effector cells
reacted against cells of another tumour
line, extracts from the same tumour as
that borne by the effector-cell donor had
no inhibitory effect. The meanpercentage
cytotoxicity of untreated and extract-
treated spleen cells showed no significant
difference (Fig. 2) and only in 6/35 (17%)
tests was the percentage cytotoxicity
inhibited > 50% (Table V).
Comparison between the 51Cr-release test and
the microcytotoxicity assay
Table V describes the results of com-
paring the 5'0r-release test and the
microcytotoxicity assay. With the micro-
cytotoxicity assay, the only tests included
are where the same target and effector-
cell populations were used in the 5'Cr-
release test. For the microcytotoxicity
assay an effector: target cell ratio of
1000: 1 and for the 51Cr-release test an
effector: target cell ratio of 200: 1 was
used throughout. In specific test com-
binations, a high frequency of cytotoxic
reactions was obtained with the micro-
cytotoxicity assay (40/43, 93%), but a
lower frequency with the 51Cr-release test
(56/97, 58%). In cross test combinations,
again the microcytotoxicity assay was
more sensitive in detecting cytotoxicity
reactions (Table V).
In comparisons of the frequency of
inhibition of tumour-bearer spleen-cell
cytotoxicity by tumour extracts in the 2
assay systems, a positive inhibition was
defined as one in which an initial cyto-
toxicity in medium-treated lymphoid cells
was reduced > 50% by extract treatment.
In specific test combinations, a high
proportion ofthe tests were detected as in-
hibited in the 51Cr-releasetest (24/34,71%)
but inhibitory responses were more fre-
quently detected in the microcytotoxicity
assay (15/15, 100%) (Table V). In cross
test combinations, the extract from the
same tumour as that borne by the effector-
cell donor wasrarely effective inmodifying
tumour-bearer lymphoid-cell cytotoxicity
in either assay.
DISCUSSION
The aim of the present study was to
develop a 51Cr-release test for the detec-
tion of cell-mediated immune reactions
and to evaluate it for the assay oftumour-
bearer spleen-cell cytotoxicity using solid
chemically induced rat hepatomas and
sarcomas. In preliminary tests, it was
determined that the optimal incubation
period for the detection of cytotoxic
reactions was 12 h. With periods up to
8 h incubation, the release of 51Cr from
cells exposed to tumour-bearer and to
normal lymphoid cells was essentially the
same. By employing incubation periods
much greater than 12 h, a rapid increase
of non-specifically released 51Cr from
labelled tumour cells in the presence of
normal and tumour-bearer effector cells
TABLE V.-CoMparison Between the 51Cr-release Test and the Mlicrocytotoxicity Assay
for the Detection of Tumour-bearer Spleen Cell Cytotoxic Reactions and Inhibition of
these Reactions by 3M KCl Extracts ofTumours
Test
combination
Specific*
Crosst
No. cytotoxic reactions (%)
No. tests
CRT$ MCA$
56/97 (58%) 40/43 (93%)
49/79 (62%) 21/31 (68%)
No. tests inhibited by 3M KCI extract (%)
No. tests
CRT: MCAt
24/34 (710%) 15/15 (100%)
6/35 (17%) 1/5 (20%)
* Spleen-cell donor, extract and target cells from same tumour line.
t Spleen-cell donor and extract from same tumour line, but target cells from a different tumour line.
4 CRT: 51Cr-release test, MCA: microcytotoxicity assay.
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prevented the detection of 51Cr release by
cell-mediated cytolysis. We assume that
the high unspecific release after more than
12 hincubation is probably due to nutrient
deprivation, especially because in samples
in which target cells were incubated with
medium alone, only a slight increase in the
5'Cr release was observed.
The modifications of the assay of
Brunner et al. (1968) adopted to maximize
the sensitivity of the test, are sum-
marized in Table VI. The preincubation
of labelled target cells for 3-4 h at 37°C
allowed the release of cell-surface-bound
label. This was necessary in order to
reduce the spontaneous release over the
long incubation period of 12 h. Effector
cells were preincubated for 12 h at 37°C
and then washed x 5, such procedure being
designed to reveal cytotoxicity in pre-
viously non-cytotoxic cell preparations,
and to remove bound serum inhibitory
factors (Laux and Lausch, 1974; Currie
and Basham, 1972; Currie, 1973). Only
small improvements were noted by this
procedure, taking effector cells from
tumour-bearing rats. But with effector
cells from tumour-immune animals (im-
munized with irradiated cells and boosted
with viable tumour cells) cytotoxicity was
only observed after preincubation of
effector cells (Z6ller, unpub.). These
observations are in agreement with the
results of Trostmann et al. (1976), who
found that 2 populations of T cells are
involved in cell-mediated cytotoxicity,
one of which first has to be activated, to
exhibit a cytotoxic reaction in the usual
short-term 51Cr release. This activation
can be partly achieved by preincubation
of effector cells at 37°C. The second
argument for preincubation of effector
cells aims at the removal of bound serum
inhibitory factors. This hypothesis was
tested by limited papain treatment of
tumour-bearer spleen cells. In fact,
papain treatment resulted in a slight
increase of the lytic potential of effector
cells, but no further improvement could
be achieved by combining both procedures
(papain treatment and preincubation).
We therefore assumed that, in our system,
preincubation of effector cells for 12 h at
37°C is sufficient to remove possible
bound serum inhibitory factors (Zoller,
unpub.).
Further small improvements were
achieved by intimate cell-to-cell contact
(gentle centrifugation ofthe target-effector
cell mixture, Thorn, Palmer and Manson,
1974) and by a final incubation at 45°C
for 1 h, which was adopted to enhance the
TABLE VI. Summary of Modifications of the 5'Cr-release Test
M1odification
Target cells
Preincubation of labelled cells for 3-4 h at 37 'C
Effector cells
Source (lymph node, spleen or peritoneal cavity)
Separation on Ficoll--Triosil
Preincubation for 12 h at 37°C
Macrophage depletion
Test procedure
Target: effector cell ratio
<1 :50
1: 100 and 1: 200
>1 :200
Sedimentation of target and effector cells
Incubation time of target and effector cells: < 8 h
8-12 h
> 12 h
Incubation at 45°C for 1 h after incubation at 37°C
Effect on the release of 5'Cr from tumour cells
in the presence of lymphoid cells from
Normal rats Tumour-bearing rats
Decrease
None
Decrease
Increase
Slight increase
None
Increase
Decrease
(shielding effect)
Slight increase
None
Increase
Increase
(nutrient depriv.)
Increase
Decrease
None
Decrease
None
None
None
None
Decrease
(shielding effect)
None
None
None
Increase
(nutrient depriv.)
None
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release of 51Cr from damaged target cells
without inducing further tumour-cell lysis
(Dunkley, Miller and Shortman, 1974).
This final version of the 5'Cr-release
test was compared with the microcyto-
toxicity assay in its ability to detect
cellular cytotoxicity of tumour-bearer
effector cells. Since no difference between
lvymph-node,spleen,andperitoneal cells was
found (Table II), only the data obtained
wxith spleen cells are presented. The model
of tumour-bearer effector cells was chosen,
because this system exhibited very in-
teresting features in a previous study
based on microcytotoxicity assay experi-
ments. We found that, as early as 2 to
3 days after tumour implantation, cyto-
toxic values were recorded. After about
14 to 18 days, cytotoxicity was no longer
demonstrable. Effector cellsfrom tumour-
bearing rats were cytotoxic in specific and
cross test combinations, and it could be
shown by inhibition with 3M KC1 extracts
oftumours and 14- to 15-day-old embryos,
that tumour-bearer effector cells were
sensitized against the individual specific
transplantation antigen of their own
tumour as well as against embryonic
antigens common to allchemically induced
tumours (hepatomas and sarcomas) tested
(Z6ller et al., 1975, 1976).
The same features of reactivity as
detected with the microcytotoxicity assay
are now described for the 51Cr-release test.
Again, a cytotoxic response was observed
soon after tumour implantation. The
highest incidence of cytotoxic reactions
was found on Days 5 to 7 (Table III) and
cytotoxicity was abolished after 14 to 18
days, depending on the tumour burden.
This phenomenon has been described by
other authors (Barski and Youn, 1969;
LeFrancois et al., 1971) and was analysed
in detail by Deckers et al. (1976), who
found that unreactivity of effector cells
from animals with large tumours depends
on the ratio of body weight to tumour
burden. They explained the phenomenon
as high-dose tolerance to tumour-asso-
ciated antigens and they showed that
immunological reactivity in general was
unchanged. Iincubation of tumour-bearer
spleen cells with 3mI KCl extracts of
tumour, containing tumour-specific
antigen, resulted in loss of cytotoxic 5'Cr
release in specific test combinations, but
only occasionally in cross test combina-
tions. This feature, being in full accor-
dance with the findings obtained bv the
microcytotoxicity assay, may be explained
by the proposal that cytolysis in
specific test combinations is predomi-
nantly, but not exclusively, directed
against tumour-specific antigens, thus
being effectively inhibited bv tumour
extracts containing this antigen. The
content of foetal antigens may also enable
the 3M% KCI extracts of tumours to inhibit
cytoloysis in cross test combinations, as
was occasionally observed.
The present work demonstrates that it
is possible to measure cytotoxic reactions
against long-term glass-adherent tumour
target cells from solid chemically induced
tumours with the 51Cr-release test. How-
ever, it should be noted that significant
cytotoxic reactions, as well as significant
inhibition of cytotoxic responses, were
more frequently detected by the micro-
cytotoxicity assay. From this we con-
cluded that the microcytotoxicity assay
is the more sensitive assay for detecting
tumour-bearer effector-cell cytotoxicity
against target cells from solid chemically
induced tumours. But the 5'Cr-release
test will prove very useful where a distinc-
tion between, for example, cytolytic
effects and adherence inhibition is at-
tempted.
It is widely held that T-cell-mediated
cytotoxicity accounts (at least in part) for
the effects observed with both the micro-
cytotoxicity assay and the 5'Cr-release
test. In the short-term 51Cr-release test,
non-T-cell effects can be predominantly
excluded. With respect to the micro-
cytotoxicity assay, various effector-cell
types and mechanisms are discussed.
In our system of chemically induced rat
hepatomas and sarcomas it is not known
whether T or non-T cells are responsible
for the cytotoxic reactions of tumour-
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bearer effector cells. Preliminary data
showed that 51Cr release is not induced by
macrophages, since carbonyl-iron treat-
ment of tumour-bearer effector cells did
not depress 51Cr release (Table II). We
cannot make any further apportionment
to T or non-T cell killing in our system.
With respect to the cytotoxic cell popula-
tion, the results ofTrostmann et al. (1976),
who has investigated, with both the
microcytotoxicity assay and the 51Cr-
release test, the cytotoxic effector cell in
an allogeneic model, should be mentioned,
because the test conditions were very
similar to ours. Trostmann and his
colleagues found that in their system, only
T-cell killing was measured in both the
microcytotoxicity assay and in the 51Cr
release test, butthattwoT-cellpopulations
were responsible for the target-cell killing,
one of which first had to be activated.
This primarily non-lytic T-cell population
was activated during the 48-h incubation
of the microcytotoxicity assay, but was
inactive in the short-term 51Cr-release test,
unless incubated with medium (partial
activation) or with the appropriate target
cell (full activation) before admixture of
target and effector cells in the 51Cr-release
test. Those findings could well explain
our results, but further studies are needed
to clarify the question of T or non-T cell
killing in tumour-bearer effector-cell cyto-
toxicity against target cells from solid
chemically induced tumours.
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